ECCEO 9-IOF | ATHENS | GREECE | March 18 - 21, 2009 | Megaron Athens International Conference Centre
Friday - MARCH 20
| 09.00 - 11.50 | SCIENTIFIC SESSION III | |
| Chairs: John A. Kanis & Jose Zanchetta | ||
| 09.00 - 09.30 | Plenary lecture 4 | |
| Clinical and economic aspects of the management of postmenopausal women with osteopenia | ||
| Speaker: Christian Roux | ||
| 09.30 - 10.00 | Oral communications selected from abstracts | |
| 10.00 - 10.30 | Plenary lecture 5 | |
| Role of microdamage in bone fragility | ||
| Speaker: Clive Lee | ||
| 10.30 - 11.50 | Oral communications selected from abstracts | |
| 12.15 - 13.45 | Lunch Symposium | Lunch Symposium |
| New insights into the pathophysiology, treatment and pharmacoeconomics of osteoarthritis |
Balancing clinical research and practical experience: the bisphosphonates | |
| Sponsored by ROTTAPHARM | MADAUS AUDITORIUM 1 - TRIANTI HALL |
sponsored by ROCHE & GLAXOSMITHKLINE AUDITORIUM 2 - SKALKOTAS HALL |
|
| Chair: T. KARACHALIOS | Chair: J.-Y. REGINSTER | |
| Role of subchondral bone in the pathophysiology of osteoarthritis J. MARTEL | Introduction The antifracture efficacy of ibandronate: a compendium of evidence J.-Y. REGINSTER |
|
| Glucosamine after the GAIT and GUIDE studies: what happened in the last two years? L.C. ROVATI | Current controversies in osteoporosis management A. SEBBA | |
| Treatment of osteoarthritis with glucosamine sulfate: from clinical to economic data O. BRUYERE & J. |
FRAX®: what it is and what it isn’t E. McCLOSKEY | |
| 13.45 - 15.00 | Poster Session & Exhibition Viewing | |
| 14.00 - 15.00 | MEET-THE-PROFESSOR SESSIONS - Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals & Sanofi-Aventis) |
|
| Use and misuse of bone densitometry in the diagnosis and follow up of osteoporotic patients - Jean-Pierre Devogelaer | ||
| Role of rehabilitation medicine in the management of osteoporosis and osteoarthritis - Olivier Bruyère | ||
| Diagnosis and management of hyperparathyroidism - John Bilezikian | ||
| 15.00 - 16.45 | SCIENTIFIC SESSION IV | |
| Chairs: Christian Roux & Dimitris Karras | ||
| 15.00 - 15.30 | Plenary lecture 6 | |
| Novelties and perspectives in the management of osteoarthritis | ||
| Speaker: Jean-Pierre Pelletier | ||
| 15.30 - 16.30 | Oral communications selected from abstracts | |
| 17.00 - 18.30 | Symposium | Symposium |
| Expanding clinical experience with bisphosphonates in osteoporosis management |
Foundation fl exibility and freedom: optimising osteoporosis treatment with PTH |
|
| Sponsored by
ALLIANCE FOR BETTER BONE HEALTH
(PROCTER & GAMBLE PHARMACEUTICALS & SANOFI-AVENTIS) AUDITORIUM 1 - TRIANTI HALL |
sponsored by NYCOMED AUDITORIUM 2 - SKALKOTAS HALL |
|
| Chairs: C. COOPER & G. SKARANTAVOS | Chair: S. MANOLAGAS | |
| Introduction G. SKARANTAVOS | New insights into the pathophysiology of osteoporosis and the effectiveness of intermittent PTH administration for its treatment S. MANOLAGAS | |
| The Global Longitudinal registry of Osteoporosis in Women (Glow): regional differences in risk factors and fragility fractures C. COOPER |
Treatment of postmenopausal women with osteoporosis using PTH(1– 84): sustained fracture prevention, increased bone mineral density and long-term safety T. KARACHALIOS | |
| New analysis from real-world clinical practices: effectiveness among bisphosphonates T. THOMAS |
Further gains, further trials: the OLES and TRES clinical studies C. WÜSTER | |
| How is safety of therapy a determinant in long-term management of osteoporosis? C. ROUX |
||
| Conclusion and Q&A session C. COOPER | ||